Numerous animal and pre-clinical model studies have shown Orynotides to be promising agents for several clinical indications, and the stability, safety profile, and biocompatibility of these cyclic peptides make them a valuable platform for drug development.
With the successful completion of our Phase 1B trial for the Treatment of Rheumatoid Arthritis (A Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ORTD 1 in Rheumatoid Arthritis Patients with Mild Disease Managed with DMARDs), the systemic safety profile of the first Orynotide therapeutic drug candidate has been validated.
